Ohio Admin. Code 4725-15-04 - Board approval of pharmacology and ocular disease continuing education course is as follows
(A) The board will approve for optometric
pharmacology continuing education compliance only those programs which relate
to:
(1) General and ocular
pharmacology
(2) Signs and symptoms
of ocular disease
(3) The
diagnosis, treatment and management of ocular disease
(4) Appropriate criteria for referring
patients to physicians and co-managing patients with physicians
(5) The use of those instruments which are
utilized in conjunction with the topical ocular pharmaceutical agents and
therapeutic pharmaceutical agents approved pursuant to section
4725.01 of the Revised
Code.
(B) Speakers,
lecturers and others participating in the presentation of the programs must be
recognized by the board as possessing requisite qualifications and being expert
and of recognized repute in their area of instruction.
(C) The course content must reflect that it
is comparable to those courses in pharmacology required by optometry boards of
other states whose licensees are permitted the use of topical ocular
pharmaceutical agents and therapeutic pharmaceutical agents in the course of
their practice of optometry.
(D)
Programs must be available to all Ohio licensed
optometrists. Limitations may be necessary based on space, time or format of
presentation and must be so noted on application. Any program that is too
restrictive may be denied approval.
(E) Programs must contribute to the
advancement of professional skill and knowledge of the participants and enable
them to render continuously better and more comprehensive optometric service to
the recipients of their care. Programs cannot be used to market the
sponsor's/presenter's products or services.
Notes
Promulgated Under: 119.03
Statutory Authority: 119.03, 4725.09
Rule Amplifies: 4725.09, 4725.16
Prior Effective Dates: 06/25/1984, 04/17/1995, 06/01/1999, 07/28/2008
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.